FY2025 EPS Forecast for Ovid Therapeutics Lowered by Analyst

Ovid Therapeutics (NASDAQ:OVID) – Equities research analysts at William Blair reduced their FY2025 earnings per share estimates for Ovid Therapeutics in a report issued on Wednesday, November 12th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.45) per share for the year, down from their prior estimate of ($0.42). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at ($0.38) EPS.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%.

Several other research analysts also recently weighed in on OVID. Oppenheimer assumed coverage on Ovid Therapeutics in a research note on Thursday, October 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Leerink Partners initiated coverage on shares of Ovid Therapeutics in a report on Monday. They issued an “outperform” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Wednesday, October 8th. Leerink Partnrs upgraded shares of Ovid Therapeutics to a “strong-buy” rating in a research report on Monday. Finally, Wall Street Zen cut shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Ovid Therapeutics has an average rating of “Buy” and a consensus price target of $3.92.

Ovid Therapeutics Trading Up 1.5%

NASDAQ OVID opened at $1.32 on Monday. The firm’s fifty day moving average is $1.44 and its two-hundred day moving average is $0.86. Ovid Therapeutics has a one year low of $0.24 and a one year high of $2.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24. The firm has a market cap of $94.00 million, a PE ratio of -2.64 and a beta of 0.32.

Institutional Trading of Ovid Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Schonfeld Strategic Advisors LLC acquired a new position in shares of Ovid Therapeutics during the 3rd quarter worth approximately $1,148,000. Affinity Asset Advisors LLC purchased a new stake in shares of Ovid Therapeutics in the first quarter valued at $208,000. Rosalind Advisors Inc. acquired a new stake in shares of Ovid Therapeutics during the second quarter valued at $165,000. Assenagon Asset Management S.A. boosted its stake in shares of Ovid Therapeutics by 112.2% during the third quarter. Assenagon Asset Management S.A. now owns 924,576 shares of the company’s stock valued at $1,202,000 after acquiring an additional 488,956 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Ovid Therapeutics during the 3rd quarter worth about $633,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.